Group 1: Share Repurchase Program - IDEX Corporation has expanded its share repurchase program, increasing total authorization to $1 billion, including $440 million remaining from the previous plan [1][8] - In the first half of 2025, IDEX repurchased shares worth $100 million and paid dividends totaling $105.9 million, reflecting a year-over-year increase of 5.2% [2][8] Group 2: Financial Expectations - For 2025, IDEX anticipates free cash flow exceeding 100% of adjusted net income, with at least 70% of this free cash flow allocated for dividends and share buybacks [3][8] - The board of directors has approved a quarterly cash dividend of 71 cents per share, payable on October 24, 2025, to shareholders of record as of October 10, 2025 [3] Group 3: Market Performance and Challenges - IDEX has a market capitalization of $12.2 billion and currently holds a Zacks Rank of 4 (Sell), facing challenges in its Fluid & Metering Technologies unit due to weaknesses in agriculture, energy, water, and semiconductor sectors [4] - The company's shares have decreased by 11.8% over the past six months, contrasting with a 9% growth in the industry [5]

Core Insights - IDEX Corporation (IEX) has underperformed in operational performance, particularly in the Fluid & Metering Technologies (FMT) segment, leading to a Zacks Rank of 4 (Sell) [1] - The stock has declined by 18.3% over the past year, contrasting with the industry's growth of 9.4% [1] Business Weakness - The FMT segment is experiencing softness, particularly in agriculture, energy, water, and semiconductor markets, with organic revenues decreasing by 2% year over year in Q2 2025 [4] - Weakness in the European chemicals market is negatively impacting the chemical businesses within the FMT segment [4] Rising Expenses - Selling, general and administrative expenses increased by 11.4% year over year in Q2 2025, with amortization and professional services spending contributing to this rise [5] - As a percentage of sales, these expenses rose by 90 basis points to 23.5% in the same period [5] - The cost of sales also saw a year-over-year increase of 7.4% in Q2 2025 [5] Forex Woes - IDEX's international operations expose it to risks from adverse currency fluctuations, particularly due to a strengthening U.S. dollar, which may pressure profit margins abroad [6][8]

July 30, 2025 Second Quarter 2025 Earnings Click Here to Edit Title Cautionary Statement Click Here to Edit Title Cautionary Statement Under the Private Securities Litigation Reform Act; Non-GAAP Measures This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, the Company's third quarter 2025 and full year 2025 outlook including expected organic sales, expected earnings ...

Financial Performance - First quarter sales increased by 2% year-over-year, from $800.5 million to $814.3 million[18, 80] - Organic sales decreased by 1%[19] - Adjusted EBITDA margin decreased by 50 bps, from 26% to 25.5%[18] - Adjusted EPS decreased by 7%, from $1.88 to $1.75[18] - Free cash flow decreased by 33%, from $136.6 million to $91.4 million[18, 82] Segment Results - Health & Science Technologies (HST) sales increased by 10%, with organic sales down by 1%[27] - Fluid & Metering Technologies (FMT) sales decreased by 7%, with organic sales down by 4%[33] - Fire & Safety/Diversified Products (FSDP) sales increased by 4%, with organic sales up by 5%[42] Guidance - The company expects organic revenue to increase by 1% to 3% for the full year 2025[49] - The company expects adjusted EBITDA to be 27.5% to 28.0% for the full year 2025[49] - The company expects adjusted EPS to be $8.10 to $8.45 for the full year 2025[49] Tariff Impact - The total annualized tariff impact is estimated to be approximately $100 million[54]

Group 1: Company Performance - IDEX Corporation (IEX) is experiencing solid momentum in the Fluid & Metering Technologies segment, with organic revenues increasing by 3% year-over-year in Q4 2024. The company anticipates overall organic revenues to rise by 1-3% year-over-year in 2025 [1] - The Health & Science Technologies segment is facing challenges, with organic revenues declining by 7% year-over-year in 2024 and remaining flat in Q4 [7] - Rising selling, general, and administrative expenses are impacting IDEX's bottom line, increasing by 14% year-over-year in Q4 2024, with costs of sales also rising by 9.7% [8] Group 2: Acquisitions and Growth Strategy - IDEX is focused on expanding its business through acquisitions, having acquired Mott Corporation for $1 billion in September 2024, enhancing its capabilities in applied materials science technology [2] - In December 2023, IDEX completed the acquisition of STC Material Solutions for $206 million, further strengthening its expertise in material sciences [3] - Acquisitions positively impacted sales by 6% in Q4 2024, indicating a successful integration of new businesses [3] Group 3: Shareholder Returns - Management is committed to rewarding shareholders, having paid dividends totaling $205.3 million in 2024, which is a 7.7% increase year-over-year [4] - The quarterly dividend rate was increased by 7.8% in May 2024, reflecting the company's focus on returning value to shareholders [4]

Group 1: Company Performance and Segments - IDEX Corporation (IEX) is expected to benefit from the strength in the Fluid & Metering Technologies segment, with organic revenues increasing by 3% year-over-year in Q4 2024 and an anticipated overall organic revenue growth of 1-3% in 2025 [1] - The company acquired Mott Corporation for $1 billion in September 2024, enhancing its applied materials science technology capabilities and micro-precision technology offerings in key markets [2] - In December 2023, IEX acquired STC Material Solutions for $206 million, which expanded its expertise in material sciences, contributing positively to sales by 6% in Q4 2024 [3] Group 2: Shareholder Returns - IEX has been committed to rewarding shareholders, with dividend payments totaling $205.3 million in 2024, reflecting a 7.7% year-over-year increase, and a 7.8% hike in its quarterly dividend rate announced in May 2024 [4] Group 3: Financial Challenges - The company faced escalating operating expenses, with a 9.7% year-over-year increase in the cost of sales and a 14% rise in selling, general, and administrative expenses in Q4 2024, leading to a 90 basis points increase in these expenses as a percentage of sales to 22.9% [7] - Weakness in the Health & Science Technologies segment due to softness in life sciences, analytical instrumentation, automotive, and semiconductor capital equipment markets raises concerns [6]